Mixed results from scheduling committee

Asthma combination medication to remain a prescription product, but new anti-histamine to be downscheduled, as latest scheduling decisions are released A proposal to downschedule the asthma combination medicine containing budesonide and formoterol has been rejected by the Therapeutic Goods Administration's Advisory Committee on Medicines Scheduling (ACMS). The results of the November hearing of the ACMS

This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.

Forgot Password?Why do I need to login & stay in?

Previous Dubbo a winner, says Minister
Next World news wrapup: 4 February 2021